| Literature DB >> 20945984 |
Mark Frasier1, Sohini Chowdhury, Jamie Eberling, Todd Sherer.
Abstract
Therapeutic development in Parkinson's disease is hampered by the paucity of well-validated biomarkers that can assist with diagnosis and/or tracking the progression of the disease. Since its inception, the Michael J Fox Foundation for Parkinson's Research has invested heavily in biomarker research and continues to prioritize discovery and development efforts. This article summarizes the history and evolution of the Michael J Fox Foundation's role in supporting biomarker research and lays out the current challenges in successfully developing markers that can be used to test therapies, while also providing a vision of future funding efforts in Parkinson's disease biomarkers.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20945984 DOI: 10.2217/bmm.10.89
Source DB: PubMed Journal: Biomark Med ISSN: 1752-0363 Impact factor: 2.851